Condition: Pneumonia · Sponsor: MiNK Therapeutics
This clinical trial will evaluate the efficacy and safety of a single intravenous dose of agenT-797 administered in addition to standard of care (SOC), compared with placebo plus SOC, in reducing short-term mortality in adult participants with severe pneumonia and moderate to severe AHRF. All participants will receive SOC management for severe pneumonia and acute respiratory distress syndrome (ARDS).
This description comes directly from the study's public registry record.
MiNK Therapeutics Clinical Trial Information · 1-212-994-8250 · webmaster@minktherapeutics.com
Always discuss trial participation with your own doctor first.
| UCSF Medical Center at Parnassus Heights | San Francisco, California, United States | Not Yet Recruiting |
| Children's Memorial Hermann Hospital | Houston, Texas, United States | Not Yet Recruiting |
| University Hospital | San Antonio, Texas, United States | Not Yet Recruiting |
| First Lviv Territorial Medical Union | Lviv, Ukraine | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07615010